Integral Molecular Announces Best-in-Class Antibodies Against Complex Oncology Target Claudin 18.2

PHILADELPHIA – Integral Molecular, the leader in discovering antibodies against multipass membrane proteins, announces fully optimized, high-affinity lead monoclonal antibodies (MAbs) against Claudin 18.2 (CLDN18.2), a structurally complex oncology target overexpressed on numerous solid tumors. The CLDN18.2 antibodies discovered using the company’s MPS antibody discovery platform are ready to progress towards preclinical studies and are … Read more

Integral Molecular Partners with China’s Leading Preclinical CRO JOINN for Comprehensive Specificity Testing of Antibodies and CAR-T Therapeutics

PHILADELPHIA – JOINN Laboratories, China’s leading preclinical contract research organization (CRO), has partnered with Integral Molecular to provide researchers in China with rapid antibody specificity testing against the entire human membrane proteome using Integral Molecular’s Membrane Proteome Array (MPA) technology. The ability to select lead candidates with high specificity will reduce safety liabilities prior to … Read more

Live Tutorial: 6 Steps to Success in Discovering Monoclonal Antibodies Against Multipass Membrane Proteins

MPS/Lipo Image

Join us for a live interactive tutorial on October 29, 2020 to learn more about using our Membrane Protein Solutions. Integral Molecular has a 95% success rate of discovering high-affinity monoclonal antibodies against multipass membrane proteins despite the structural complexity and low immunogenicity of these targets. Here, we present some of the lessons we have … Read more

Totient Leverages Integral Molecular’s Membrane Proteome Array to Advance Cancer Therapeutic Discovery

PHILADELPHIA – Integral Molecular and Totient announce a partnership leveraging Integral Molecular’s Membrane Proteome Array (MPA) target identification technology to advance the discovery of antibodies for cancer therapy. Totient reconstructs antibodies from tertiary lymphoid structures (TLS), which are structures formed in tissues affected by autoimmunity, infections, and cancer, collected from patients experiencing exceptional immune responses. … Read more

Integral Molecular Awarded Grant from the Commonwealth of Pennsylvania to Advance COVID-19 Research

PHILADELPHIA – Integral Molecular has been awarded $521,723 from the Commonwealth of Pennsylvania to leverage its technologies in the global fight against COVID-19. Integral Molecular is at the forefront of the fight against COVID-19, with their technologies being used by over 100 laboratories worldwide to advance COVID-19 vaccine and therapeutic development. This grant will enable … Read more

Integral Molecular & Fierce Bio Present: De-risk Antibody and CAR-T Safety by Identifying Off-target Specificity Webinar

The long-held assumption that antibodies are exquisitely specific is being re-examined since 25% of monoclonal antibodies (MAbs) show polyspecificity and bind unintended targets. This Fierce webinar brings together experts with experience in biotech, pharma, and the FDA to discuss the latest technologies and strategies to optimize IND safety data packages. Topics to be discussed include: … Read more

Humanized Chicken Antibody Technology to Drive Next Generation of Integral Molecular’s MPS Antibody Discovery Platform

PHILADELPHIA – Integral Molecular announces the development of Humanized Chicken Antibody Technology (hCAT) and the incorporation of hCAT into the company’s industry-leading MPS antibody discovery platform for multipass membrane proteins. The innovation of hCAT lies in the ability to isolate fully humanized antibodies directly from immunized animals, reducing the time and effort needed for antibody … Read more